Loading…
Loading the latest PSX data…
Loading the latest PSX data…
GlaxoSmithKline Pakistan Limited (GLAXO), Abbott Laboratories (Pakistan) Limited (ABOT), Haleon Pakistan Limited (HALEON): performance, valuation, growth, risk and danioPSX score, side by side.
Add a stock
Growth of Rs 100 from 2025-11-11
Daily closes from PSX end-of-day files, adjusted for bonus shares, right issues and splits (not for cash dividends). KSE-100: official closes where available, otherwise rebuilt from its constituents.
| Measure | GLAXOPharmaceuticals | ABOTPharmaceuticals | HALEONPharmaceuticals |
|---|---|---|---|
| danioPSX score | 89 | 80 | 65 |
| Price and size | |||
| Price | Rs 339.59 | Rs 1,003.93 | Rs 689.69 |
| Today | +0.96% | +0.39% | −1.06% |
| Market cap | Rs 108.1bn | Rs 98.3bn | Rs 80.7bn |
| Traded per day | Rs 49m | Rs 14m | Rs 20m |
| Valuation and dividends | |||
| P/E | 9.9 | 10.6 | 12.4 |
| Dividend yield | 6.1% | 4.4% | 3.6% |
| EPS (last year) | Rs 31.48 | Rs 81.37 | Rs 54.45 |
| Business | |||
| EPS growth | +53.4% | +52.2% | +39.2% |
| Sales growth | +7.7% | +10.6% | +15.9% |
| Net margin | 15.2% | 10.6% | 14.8% |
| Returns | |||
| 1 month | +8.9% | +7.5% | +1.7% |
| 3 months | −1.6% | +9.4% | −7.6% |
| 1 year | −13.9% | −8.1% | −15.7% |
| vs KSE-100, 1 year | -27.0 pts | -21.2 pts | -28.8 pts |
| Trend and risk | |||
| 52-week position | 28% | 40% | 11% |
| RSI 14 | 65 | 66 | 55 |
| RS rank | 42 | 64 | 27 |
| Volatility | 34% | 30% | 30% |
| Beta | 1.05 | 0.77 | 0.86 |
| danioPSX score | |||
| Value | 69 | 61 | 42 |
| Quality | 81 | 74 | 79 |
| Dividend | 64 | 34 | 45 |
| Momentum | 40 | 59 | 26 |
| Safety | 80 | 76 | 78 |
| Shariah-compliant | Yes | Yes | Yes |
Bold marks the best value in each row where higher (or, for P/E and volatility, lower) is clearly better.
A comparison of published numbers, not a recommendation. Share this page: the address holds the stocks. Find more stocks with the screener